What Are the Barriers to Optimal Care?
Release Date: February 12, 2014
Expiration Date: February 12, 2015
Expected time to complete this activity as designed: 30 minutes
There are no fees for participating in or receiving credit for this online activity.
During the last decade, the treatment of multiple myeloma has changed dramatically. What was once a small-incidence hematologic malignancy with survival times of less than 3 years for a majority of patients has, through dedicated research and innovative treatment advances, evolved into a disease where median survival is now greater than 7 years. Through use of new agents and approaches to sequencing that effectively combine older and new pharmacologic options while better managing treatment-associated side effects and comorbidities, many community oncologists are able to provide vastly improved care to their patients.
These advances, however, only represent one facet of the evolving treatment paradigm of multiple myeloma, and numerous but exciting challenges remain. Clinicians that provide care for patients with multiple myeloma are now faced with a different set of treatment and management barriers, many of which are new to the multidisciplinary myeloma patient care team.
This activity is designed for physicians, physician assistants, and pharmacists who have an interest in enhancing their clinical skills in treating patients with multiple myeloma.
Upon completion of this educational activity, participants should be able to:
- Describe the potential role of new approaches for minimum residual disease detection
- Summarize the essentials for monitoring treatment adherence and survivorship planning
Kenneth C. Anderson, MD – Moderator
Beth Faiman, PhDc, RN, MSN, APRN-BC, AOCN® – Panelist
Benyam Muluneh, PharmD, BCOP, CPP – Panelist
Instructions for Participation and Credit
This activity is eligible for credit through February 12, 2015. After this date, this activity will expire and no further credit will be awarded.
- Read the target audience, learning objectives, and faculty disclosures.
- You may be asked to complete a short pre-test before accessing the educational content. This must be completed in order to move forward in the activity.
- Complete the educational content as designed.
- Complete the post-test. To receive a certificate, you must receive a passing score of 70%.
- Complete the activity evaluation survey to provide feedback and information useful for future programming.
- Certificates may be printed immediately after successfully completing the post-test and activity evaluation.
Kenneth C. Anderson, MD
Kraft Family Professor of Medicine
Harvard Medical School
Chief, Division of Hematologic Neoplasia
Director, Jerome Lipper Multiple Myeloma Center
Director, LeBow Institute for Myeloma Therapeutics
Dana-Farber Cancer Institute
Dr. Kenneth Anderson graduated from Johns Hopkins Medical School, trained in internal medicine at Johns Hopkins Hospital, and completed hematology, medical oncology, and tumor immunology training at the Dana-Farber Cancer Institute. He is the Kraft Family Professor of Medicine at Harvard Medical School; and serves as chief of the Division of Hematologic Neoplasia, director of the LeBow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center, and vice chair of the Joint Program in Transfusion Medicine at Dana-Farber Cancer Institute.
Dr. Anderson serves as chair of the NCCN Multiple Myeloma Clinical Practice Guidelines Committee; as a Cancer and Leukemia Group B Principal Investigator; on the Board of Scientific Advisors of the International Myeloma Foundation; and is on the Board of Directors and Chair of both the Scientific Advisory Board of the Multiple Myeloma Research Foundation and the Steering Committee of the Multiple Myeloma Research Consortium. Dr. Anderson has published more than 350 original articles, 250 chapters, has edited multiple textbooks on both multiple myeloma and on transfusion medicine, and was named editor in chief of Clinical Cancer Research. In addition, he is a Doris Duke Distinguished Clinical Research Scientist and has received numerous other awards.
Over the last two decades, Dr. Anderson has focused his translational research studies on B-cell malignancies, especially multiple myeloma. His team led both preclinical and clinical trials of the novel proteasome inhibitor bortezomib, as well as lenalidomide. His research offers great promise to improve patient outcome in hematologic malignancies and solid tumors.
Beth Faiman, PhDc, RN, MSN, APRN-BC, AOCN®
Multiple Myeloma Program
Cleveland Clinic Foundation
Beth Faiman received her master of science degree in nursing and certification as an adult nurse practitioner at Kent State University, Ohio. She holds an advanced oncology nurse certification through ANCC and is a pre-doctoral research fellow at the Frances Payne Bolton School of Nursing at Case Western Reserve in Cleveland, Ohio. Ms. Faiman is currently employed as an adult nurse practitioner at the Cleveland Clinic.
A member of several professional associations including the Oncology Nursing Society, Cleveland Chapter Oncology Nursing Society, Ohio Academy of Advanced Practice Nurses, and American Association of Nurse Practitioners, Ms. Faiman is also co-chair of the Nurses Excellence Awards Committee for the Cleveland Clinic, and is current chair of the Advanced Practice Nurse Council for the Cleveland Clinic. In addition, she is an appointed delegate on the Nursing Leadership Board for the International Myeloma Foundation. Ms. Faiman is the editor-in-chief of The Oncology Nurse. She has co-authored several articles relating to the treatment of refractory and relapsing myeloma treatment and has been published in Mayo Clinic Proceedings, Clinical Journal of Oncology Nursing, and has authored several chapters related to diagnosis and management of multiple myeloma. Ms. Faiman is an active presenter and educator on the topics of multiple myeloma, general cancer diagnosis and treatment, as well as management of skeletal and other cancer complications.
Benyam Muluneh, PharmD, BCOP, CPP
Malignant Hematology Clinic
University of North Carolina Health Care
Chapel Hill, North Carolina
Dr. Benyam Muluneh received his doctor of pharmacy degree from the University of North Carolina (UNC) Eshelman School of Pharmacy, Chapel Hill. He also completed a hematology/oncology specialty residency as well as a pharmacy practice residency at UNC Hospitals. Dr. Muluneh is a board certified oncology pharmacist and clinical pharmacist practitioner and holds memberships in the American College of Clinical Pharmacy (ACCP) and American Society of Health-System Pharmacists (ASHP). He is a clinical pharmacist at the Malignant Hematology Clinic, UNC Health Care in Chapel Hill.
Accreditation Statement: MediCom Worldwide, Inc. is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Designation Statement: MediCom Worldwide, Inc. designates this enduring material for a maximum of .5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MediCom Worldwide, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is acceptable for .5 contact hours of Continuing Education Credit. Universal Activity Number: 827-0000-14-387-H01-P. Knowledge-based CPE activity.
In order for CPE Monitor to authenticate credit, pharmacists/technicians must provide their e-Profile ID number from NABP and date of birth (in MMDD format) when registering for a CPE program. Please make sure to provide this information in your Member Profile accessed through the Member Center on the home page of this site.
As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest. Accordingly, the following disclosures were made.
Dr. Kenneth Anderson has received honoraria related to formal advisory activities from Celgene Corporation, Gilead, Onyx, and sanofi-aventis U.S. LLC. He is the scientific founder of Acetylon Pharmaceuticals, Inc. and OncoPep.
Beth Faiman has received honoraria related to speakers’ bureau activities and as a consultant from Celgene Corporation, Millennium Pharmaceuticals, Inc. (A wholly-owned subsidiary of Takeda Pharmaceutical Company Limited), and Onyx.
Dr. Benyam Muluneh has disclosed no relevant financial relationships.
Planning Committee Disclosures
The individuals listed below from MediCom Worldwide, Inc. reported the following for this activity: Joan Meyer, RN, MHA, executive director, and Eugene R. Tombler, PhD, FACME, medical director, oncology, have no relevant financial relationships.
Peer Reviewer Disclosure
In accordance with MediCom Worldwide, Inc. policy, all content is reviewed by external independent peer reviewers for balance, objectivity and commercial bias. The peer reviewers have no relevant financial relationships to disclose.
Off-Label Disclosures/Investigational Disclosures
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. Further, attendees/participants should appraise the information presented critically and are encouraged to consult appropriate resources for any product or device mentioned in this program.
Dr. Anderson and Beth Faiman have indicated that they do intend to discuss off-label uses of drugs, mechanical devices, biologics or diagnostics approved by the US Food and Drug Administration (FDA) for use in the US.
Dr. Anderson and Beth Faiman have indicated that they do intend to discuss investigational drugs, mechanical devices, biologics or diagnostics not approved by the FDA for use in the US.
Dr. Muluneh has indicated that he does not intend to discuss off-label uses of drugs, mechanical devices, biologics or diagnostics approved by the US Food and Drug Administration (FDA) for use in the US.
Dr. Muluneh has indicated that he does not intend to discuss investigational drugs, mechanical devices, biologics or diagnostics not approved by the FDA for use in the US.
MediCom Worldwide, Inc. requires Internet Explorer® version 9.0 or higher, the latest version of Google Chrome, or the latest version of Safari, a computer running Windows® Vista, Windows® 7, or Mac OS X, 512MB of RAM or greater, 1.5 GHZ or faster processor, and a screen resolution of 1024x768 or higher. Certain educational activities may require additional software to view. These activities will be marked with the information and/or links to the required software. That software may include Adobe® Flash® Player, Adobe® Acrobat®, Windows Media® Player, and/or Microsoft® Silverlight™.
If you have any questions or concerns regarding this activity, please contact MediCom Worldwide, Inc. at 1-800-408-4242 or email us at email@example.com.
Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Millennium: The Takeda Oncology Company and Celgene Corporation.
©2014 MediCom Worldwide, Inc., 101 Washington St., Morrisville, PA 19067, 800-408-4242.
No portion of this material may be copied or duplicated without the expressed permission of MediCom Worldwide, Inc.